

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 December 2021 (23.12.2021)



(10) International Publication Number

WO 2021/254981 A1

- (51) **International Patent Classification:**
C07D 265/28 (2006.01) C07D 471/04 (2006.01)
- (21) **International Application Number:**
PCT/EP2021/066019
- (22) **International Filing Date:**
15 June 2021 (15.06.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
20180229.5 16 June 2020 (16.06.2020) EP
- (71) **Applicant: ADVERIO PHARMA GMBH** [DE/DE];
Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE).
- (72) **Inventors: FEY, Peter;** Am Eickhof 23, 42111 Wuppertal (DE). **BREMEYER, Nadine;** Xantener Strasse 6, 40474 Düsseldorf (DE). **LONGERICH, Markus;** Takustraße 41a, 50825 Köln (DE). **FRENZEL, Thomas;** Rungestraße 47, 51061 Köln (DE). **FABER, Helene;** Kollwitzstr. 77, 41539 Dormagen (DE). **SOWA, Michal;** Kempers Häuschen 10, 42109 Wuppertal (DE). **BROCKOB, Joerg;** Steinstr. 56, 51379 Leverkusen (DE). **BECKER, Guido;** Bodelschwinghstr. 20, 47800 Krefeld (DE). **NEUMANN, Heike;** Hindenburgstr. 143, 42117 Wuppertal (DE).
- (74) **Agent: BIP PATENTS;** Alfred-Nobel-Str. 10, 40789 Monheim am Rhein NRW (DE).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

- with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) **Title:** PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-b]PYRIDIN-3-YL]PYRIMIDIN-5-YL}CARBAMATE



(I)

(57) **Abstract:** The present application relates to a novel and efficient process with high yield for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate of the formula (I) in the crystalline form of modification I, wherein the x-ray diffractogram of the compound of the formula (I) in modification I exhibits peak maxima of the 2 theta angle at 5.9, 6.9, 22.7, in very high purity which is significantly more cost-effective than the process known from the art and can be performed in customary pilot- and production plant-equipment (stirred tank/devices for isolation).

WO 2021/254981 A1